The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)

被引:1
|
作者
Li, Shu-Jing [1 ]
Liu, An-Bu [2 ]
Yu, Yuan-Yuan [2 ]
Ma, Jin-Hai [1 ]
机构
[1] Ningxia Med Univ, Gen Hosp, Dept Pediat Med, Yinchuan, Ningxia, Peoples R China
[2] Ningxia Med Univ, Gen Hosp, Dept Emergency Med, Yinchuan, Ningxia, Peoples R China
来源
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2024年 / 12卷
关键词
non-alcoholic fatty liver disease (NAFLD); pyroptosis; NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome; gasdermin D (GSDMD); caspase; targeted therapy; NLRP3 INFLAMMASOME ACTIVATION; HEPATOCYTE PYROPTOSIS; HEPATIC STEATOSIS; CELL-DEATH; FIBROSIS; STEATOHEPATITIS; NASH; INHIBITOR; APOPTOSIS; LIPOTOXICITY;
D O I
10.3389/fcell.2024.1407738
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome characterized by the excessive accumulation of fat within liver cells, which can progress to end-stage liver disease in severe cases, posing a threat to life. Pyroptosis is a distinct, pro-inflammatory form of cell death, differing from traditional apoptosis. In recent years, there has been growing research interest in the association between pyroptosis and NAFLD, encompassing the mechanisms and functions of pyroptosis in the progression of NAFLD, as well as potential therapeutic targets. Controlled pyroptosis can activate immune cells, eliciting host immune responses to shield the body from harm. However, undue activation of pyroptosis may worsen inflammatory responses, induce cellular or tissue damage, disrupt immune responses, and potentially impact liver function. This review elucidates the involvement of pyroptosis and key molecular players, including NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome, gasdermin D (GSDMD), and the caspase family, in the pathogenesis and progression of NAFLD. It emphasizes the promising prospects of targeting pyroptosis as a therapeutic approach for NAFLD and offers valuable insights into future directions in the field of NAFLD treatment.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Role of the inflammasome, gasdermin D, and pyroptosis in non-alcoholic fatty liver disease
    Rodriguez-Antonio, Itzayana
    Lopez-Sanchez, Guillermo N.
    Uribe, Misael
    Chavez-Tapia, Norberto C.
    Nuno-Lambarri, Natalia
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (10) : 2720 - 2727
  • [2] Non-alcoholic fatty liver disease (NAFLD)
    Rau, Monika
    Weiss, Johannes
    Geier, Andreas
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2015, 140 (14) : 1051 - +
  • [3] The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment
    Yu, Lili
    Hong, Wei
    Lu, Shen
    Li, Yanrong
    Guan, Yaya
    Weng, Xiaogang
    Feng, Zhiwei
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [4] Role of Leptin in Non-Alcoholic Fatty Liver Disease
    Jimenez-Cortegana, Carlos
    Garcia-Galey, Alba
    Tami, Malika
    del Pino, Pilar
    Carmona, Isabel
    Lopez, Soledad
    Alba, Gonzalo
    Sanchez-Margalet, Victor
    BIOMEDICINES, 2021, 9 (07)
  • [5] Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD)
    Vizzutti, Francesco
    Arena, Umberto
    Nobili, Valerio
    Tarquini, Roberto
    Trappoliere, Marco
    Laffi, Giacomo
    Marra, Fabio
    Pinzani, Massimo
    ANNALS OF HEPATOLOGY, 2009, 8 (02) : 89 - 94
  • [6] Diagnosis of non-alcoholic fatty liver disease (NAFLD)
    Yki-Jarvinen, Hannele
    DIABETOLOGIA, 2016, 59 (06) : 1104 - 1111
  • [7] The Potential Role of Cellular Senescence in Non-Alcoholic Fatty Liver Disease
    Engelmann, Cornelius
    Tacke, Frank
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (02)
  • [8] Non-alcoholic fatty liver disease
    Neuschwander-Tetri, Brent A.
    BMC MEDICINE, 2017, 15
  • [9] Experimental model and novel therapeutic targets for non-alcoholic fatty liver disease development
    Jin, Yujin
    Heo, Kyung-Sun
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2023, 27 (04) : 299 - 310
  • [10] What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?
    Huber, Yvonne
    Galle, Peter R.
    Schattenberg, Joern M.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (01): : 68 - 73